GZD824 is primarily utilized in the field of cancer research and treatment. It functions as a potent inhibitor of BCR-ABL tyrosine kinase, which is a key driver in certain types of leukemia, particularly chronic myeloid leukemia (CML). By targeting and inhibiting this kinase, GZD824 effectively disrupts the signaling pathways that promote the growth and survival of cancer cells. This makes it a valuable compound in the development of targeted therapies aimed at managing and treating CML. Additionally, its ability to overcome resistance to other tyrosine kinase inhibitors enhances its potential as a therapeutic agent in cases where traditional treatments have failed. Ongoing research continues to explore its efficacy and safety in clinical settings, with the goal of improving outcomes for patients with leukemia.